{"brief_title": "A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients", "brief_summary": "The purpose of this study is to determine if IDN-6556, when given orally, is safe and effective in patients with chronic hepatitis C virus infection.", "condition": ["Hepatitis C, Chronic"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["IDN-6556", "Placebo"], "arm_group_label": ["IDN-6556 5 mg twice a day (BID)", "IDN-6556 25mg twice a day (BID)", "IDN-6556 50 mg twice a day (BID)", "Placebo"], "criteria": "Inclusion Criteria: - Chronic hepatitis C infection - Unsuccessful prior HCV treatment - Liver impairment (either AST or ALT 1.5-10.0 x ULN) - Alpha-fetoprotein <= 50 ng/mL - Adequate hematologic parameters Exclusion Criteria: - Decompensated or severe liver disease - Hepatocellular carcinoma - HIV infection - Co-infection with hepatitis B virus (HBV) - Renal impairment - Pancreatitis - Use of illicit or drugs of abuse - History of alcohol abuse - Presence of clinically significant cardiac arrhythmias - If female, pregnant or lactating", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Hepatitis", "Hepatitis A", "Hepatitis C", "Hepatitis C, Chronic", "Caspase Inhibitors"], "id": "NCT00088140"}